Following FDA Review Company to Initiate Clinical Trial for the Treatment of HER2 Expressing Solid-Tumors
PRINCETON, NJ, USA I January 5, 2015 I Advaxis, Inc.(ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS-HER2 (ADXS31-164) for the treatment of HER2 expressing solid tumors. The trial will be initiated in the first quarter of 2015. In May 2014, Advaxis was granted orphan drug designation for ADXS-HER2 in osteosarcoma.
Pending FDA’s acceptance of the IND submission, the proposed study is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic HER2 expressing solid tumors which include breast, gastric, esophageal, and osteosarcoma. Within 30 calendar days of the IND filing, FDA will notify Advaxis of any questions it has or protocol revisions it requests which may delay initiation of the proposed study.
“This clinical trial will provide us with information that allows us to more fully understand the potential of ADXS-HER2 in HER2 expressing cancers, such as breast, gastric, esophageal cancers, and osteosarcoma,” stated Daniel J. O’Connor, President and Chief Executive Officer of Advaxis.
About HER2 Expressing Solid Tumor Cancers
HER2 is expressed in a percentage of solid tumors such as breast, bladder, pancreatic, gastric, ovarian cancers and osteosarcoma. The American Cancer Society estimates that in 2014 in the United States (US) alone there will be 232,670 diagnoses of invasive breast cancer, 22,220 new cases of gastric cancer, 74,690 new cases of bladder cancer, 46,420 new cases of pancreatic cancer, 22,220 new cases of gastric cancer, 21,980 new cases of ovarian cancer, and 800 new cases of osteosarcoma.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’s ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.
Advaxis’s second Lm-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. (“Merck”), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s PD-1 checkpoint inhibitor KEYTRUDA(R) (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.
Advaxis is also developing Lm-LLO immunotherapy ADXS-cHER2, to target the Her2 receptor expressing cancers. Her2 is expressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.
SOURCE: Advaxis
Post Views: 229
Following FDA Review Company to Initiate Clinical Trial for the Treatment of HER2 Expressing Solid-Tumors
PRINCETON, NJ, USA I January 5, 2015 I Advaxis, Inc.(ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS-HER2 (ADXS31-164) for the treatment of HER2 expressing solid tumors. The trial will be initiated in the first quarter of 2015. In May 2014, Advaxis was granted orphan drug designation for ADXS-HER2 in osteosarcoma.
Pending FDA’s acceptance of the IND submission, the proposed study is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic HER2 expressing solid tumors which include breast, gastric, esophageal, and osteosarcoma. Within 30 calendar days of the IND filing, FDA will notify Advaxis of any questions it has or protocol revisions it requests which may delay initiation of the proposed study.
“This clinical trial will provide us with information that allows us to more fully understand the potential of ADXS-HER2 in HER2 expressing cancers, such as breast, gastric, esophageal cancers, and osteosarcoma,” stated Daniel J. O’Connor, President and Chief Executive Officer of Advaxis.
About HER2 Expressing Solid Tumor Cancers
HER2 is expressed in a percentage of solid tumors such as breast, bladder, pancreatic, gastric, ovarian cancers and osteosarcoma. The American Cancer Society estimates that in 2014 in the United States (US) alone there will be 232,670 diagnoses of invasive breast cancer, 22,220 new cases of gastric cancer, 74,690 new cases of bladder cancer, 46,420 new cases of pancreatic cancer, 22,220 new cases of gastric cancer, 21,980 new cases of ovarian cancer, and 800 new cases of osteosarcoma.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’s ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.
Advaxis’s second Lm-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. (“Merck”), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s PD-1 checkpoint inhibitor KEYTRUDA(R) (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.
Advaxis is also developing Lm-LLO immunotherapy ADXS-cHER2, to target the Her2 receptor expressing cancers. Her2 is expressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.
SOURCE: Advaxis
Post Views: 229
